Esken Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.30 Cr
as on 05-01-2025
- Paid Up Capital ₹ 1.59 Cr
as on 05-01-2025
- Company Age 32 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 2.84 Cr
as on 05-01-2025
- Revenue -51.95%
(FY 2020)
- Profit -74.72%
(FY 2020)
- Ebitda -364.43%
(FY 2020)
- Net Worth -46.31%
(FY 2020)
- Total Assets -11.85%
(FY 2020)
About Esken Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 6.30 Cr and a paid-up capital of Rs 1.59 Cr.
The company has closed loans amounting to ₹2.84 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ashishkumar Patel, Pranavkumar Patel, and Nigamkumar Patel serve as directors at the Company.
- CIN/LLPIN
U24231GJ1992PLC017941
- Company No.
017941
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Jul 1992
- Date of AGM
25 Feb 2023
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Esken Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashishkumar Patel  | Whole-Time Director | 06-Jul-1997 | Current |
| Pranavkumar Patel | Whole-Time Director | 06-Jul-1997 | Current |
| Nigamkumar Patel | Whole-Time Director | 06-Jul-1997 | Current |
Financial Performance of Esken Pharmaceuticals.
Esken Pharmaceuticals Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 51.95% decrease. The company also saw a substantial fall in profitability, with a 74.72% decrease in profit. The company's net worth observed a substantial decline by a decrease of 46.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Esken Pharmaceuticals?
In 2019, Esken Pharmaceuticals had a promoter holding of 15.79% and a public holding of 84.21%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 May 2016 | ₹2.25 Cr | Satisfied |
The Co-Operative Bank Of Mehsana Limited Creation Date: 26 Feb 2009 | ₹2.50 M | Satisfied |
The Co-Operative Bank Of Mehsana Limited Creation Date: 05 Jul 2008 | ₹2.50 M | Satisfied |
How Many Employees Work at Esken Pharmaceuticals?
Esken Pharmaceuticals has a workforce of 3 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Esken Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Esken Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
